HanchorBio, Inc.

New Capabilities

As of October 2026: Clinical-stage biotech, TSE-listed (7827), trispecific immunotherapies for oncology

The U.S. Food and Drug Administration cleared HanchorBio's investigational new drug application for HCB303 on October 5, and three days later the company filed the same drug with Taiwan's TFDA. HCB303 is a single fusion protein that blocks three immune pathways: TIGIT, PD-L1, and CD47.

Updated Oct 8